Gu X, Minko T
Cancers (Basel). 2024; 16(8).
PMID: 38672671
PMC: 11048786.
DOI: 10.3390/cancers16081589.
Garbuzenko O, Sapiezynski J, Girda E, Rodriguez-Rodriguez L, Minko T
Small. 2024; 20(41):e2307462.
PMID: 38342698
PMC: 11316847.
DOI: 10.1002/smll.202307462.
Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M
ACS Omega. 2023; 8(1):10-41.
PMID: 36643475
PMC: 9835549.
DOI: 10.1021/acsomega.2c04078.
Salahuddin N, Awad S, Elfiky M
RSC Adv. 2022; 12(33):21422-21439.
PMID: 35975070
PMC: 9346502.
DOI: 10.1039/d2ra02717h.
Majumder J, Minko T
Adv Ther (Weinh). 2020; 4(2):2000203.
PMID: 33173809
PMC: 7646027.
DOI: 10.1002/adtp.202000203.
Supramolecular Vesicles Based on Amphiphilic Pillar[n]arenes for Smart Nano-Drug Delivery.
Hua Y, Chen L, Hou C, Liu S, Pei Z, Lu Y
Int J Nanomedicine. 2020; 15:5873-5899.
PMID: 32848395
PMC: 7429218.
DOI: 10.2147/IJN.S255637.
Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer.
Entezar-Almahdi E, Mohammadi-Samani S, Tayebi L, Farjadian F
Int J Nanomedicine. 2020; 15:5445-5458.
PMID: 32801699
PMC: 7398750.
DOI: 10.2147/IJN.S257700.
TrkC-Targeted Kinase Inhibitors And PROTACs.
Zhao B, Burgess K
Mol Pharm. 2019; 16(10):4313-4318.
PMID: 31512882
PMC: 7034693.
DOI: 10.1021/acs.molpharmaceut.9b00673.
Nanocarrier-based systems for targeted and site specific therapeutic delivery.
Majumder J, Taratula O, Minko T
Adv Drug Deliv Rev. 2019; 144:57-77.
PMID: 31400350
PMC: 6748653.
DOI: 10.1016/j.addr.2019.07.010.
Controlled Drug Delivery Systems for Oral Cancer Treatment-Current Status and Future Perspectives.
Ketabat F, Pundir M, Mohabatpour F, Lobanova L, Koutsopoulos S, Hadjiiski L
Pharmaceutics. 2019; 11(7).
PMID: 31262096
PMC: 6680655.
DOI: 10.3390/pharmaceutics11070302.
Metastatic and triple-negative breast cancer: challenges and treatment options.
Al-Mahmood S, Sapiezynski J, Garbuzenko O, Minko T
Drug Deliv Transl Res. 2018; 8(5):1483-1507.
PMID: 29978332
PMC: 6133085.
DOI: 10.1007/s13346-018-0551-3.
Near-Infrared Activated Release of Doxorubicin from Plasmon Resonant Liposomes.
Knights-Mitchell S, Romanowski M
Nanotheranostics. 2018; 2(4):295-305.
PMID: 29977741
PMC: 6030767.
DOI: 10.7150/ntno.22544.
Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.
Mangal S, Gao W, Li T, Zhou Q
Acta Pharmacol Sin. 2017; 38(6):782-797.
PMID: 28504252
PMC: 5520191.
DOI: 10.1038/aps.2017.34.
Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide.
Liu X, Zhu L, Ma J, Qiao X, Zhu D, Liu L
Drug Deliv Transl Res. 2016; 7(1):147-155.
PMID: 27896668
DOI: 10.1007/s13346-016-0348-1.
Highly Stable PEGylated Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for the Effective Delivery of Docetaxel in Prostate Cancers.
Cao L, Zeng S, Zhao W
Nanoscale Res Lett. 2016; 11(1):305.
PMID: 27325521
PMC: 4916070.
DOI: 10.1186/s11671-016-1509-3.
Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.
Burns K, Robinson M, Thevenin D
Mol Pharm. 2015; 12(4):1250-8.
PMID: 25741818
PMC: 4476257.
DOI: 10.1021/mp500779k.
Targeted PDT agent eradicates TrkC expressing tumors via photodynamic therapy (PDT).
Kue C, Kamkaew A, Lee H, Chung L, Kiew L, Burgess K
Mol Pharm. 2014; 12(1):212-22.
PMID: 25487316
PMC: 4291778.
DOI: 10.1021/mp5005564.
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Hoch U, Staschen C, Johnson R, Eldon M
Cancer Chemother Pharmacol. 2014; 74(6):1125-37.
PMID: 25228368
PMC: 4236622.
DOI: 10.1007/s00280-014-2577-7.
TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells.
Liu L, Dong X, Zhu D, Song L, Zhang H, Leng X
Int J Nanomedicine. 2014; 9:2879-89.
PMID: 24959076
PMC: 4061174.
DOI: 10.2147/IJN.S61392.
LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.
Wen D, Chitkara D, Wu H, Danquah M, Patil R, Miller D
Pharm Res. 2014; 31(10):2784-95.
PMID: 24789451
DOI: 10.1007/s11095-014-1375-6.